IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy

Adi Jacob Berger, Elinor Gigi, Lana Kupershmidt, Zohar Meir, Nancy Gavert, Yaara Zwang, Amir Prior, Shlomit Gilad, Uzi Harush, Izhak Haviv, Salomon M. Stemmer, Galia Blum, Emmanuelle Merquiol, Mariya Mardamshina, Sivan Kaminski Strauss, Gilgi Friedlander, Jair Bar, Iris Kamer, Yitzhak Reizel, Tamar GeigerYitzhak Pilpel, Yishai Levin, Amos Tanay, Baruch Barzel, Hadas Reuveni, Ravid Straussman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences